3 terminated, 2 active not recruiting, 1 completed, 1 not yet recruiting. 7 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 3, Active not recruiting 1, Completed 1, Recruiting 1, Unknown 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Antithymocyte Globulin (ATG): new trials by email Literature Review of Antithymocyte Globulin (ATG) trials Research Report on Antithymocyte Globulin (ATG)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients Venetoclax, Azacitidine (AZA), Decitabine 20 mg/m²/day for 5 days - Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT) | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 42 | 2026-08-01 | 2026-08-19 |
| Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG Antithymocyte Globulin (ATG), Teplizumab - Type 1 Diabetes Mellitus | Phase 2 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 60 | 2026-07-29 | 2026-09-09 |
| BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar - Transplant Rejection | Phase 2 | Active not recruiting | Sanofi | 48 | 2022-06-09 | 2026-08-21 |
| Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation Busulfan 3.2 mg/kg/day, Fludarabine, Melphalan - Hematologic Malignancies | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 39 | 2019-09-18 | 2026-10-23 |
| Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) Antithymocyte Globulin (ATG), Fludarabine, Cyclophosphamide - Severe Aplastic Anemia | Phase 2 | Completed | Medical College of Wisconsin | 32 | 2017-07-03 | 2026-03-31 |
| Cord Blood Transplantation for Patients With Cancer Melphalan, Fludarabine, Antithymocyte Globulin (ATG) - Hematological Disease | Phase 2 | Terminated | University of Chicago | 1 | 2010-04-01 | 2015-04-30 |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation Visilizumab, Tacrolimus, Methotrexate - Graft Versus Host Disease | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 8 | 2007-12-01 | 2014-07-18 |
| Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome Antithymocyte globulin (ATG), Prednisone - Myelodysplastic Syndrome | Phase 2 | Unknown | Office of Rare Diseases (ORD) | 54 | 2007-04-01 | 2009-06-02 |
| Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients Imatinib Mesylate, Fludarabine (Fludara), Busulfan - Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 42 | 2003-02-01 | 2012-04-23 |
Leukemia (3) · Anemia, Aplastic (2) · Hematologic Neoplasms (2) · Myelodysplastic Syndromes (2) · Autoimmune Diseases (1) · Diabetes Mellitus, Type 1 (1) · Graft vs Host Disease (1) · Hematologic Diseases (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Multiple Myeloma (1) · Primary Myelofibrosis (1)
H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Office of Rare Diseases (ORD) (1) · Sanofi (1) · The First Affiliated Hospital of Soochow University (1) · University of Chicago (1)
United States (8) · Canada (1) · China (1) · France (1) · Germany (1) · Italy (1) · Spain (1) · Sweden (1)
Alan List, MD (1) · Andrew Artz, MD (1) · David Baidal, MD (1) · Lia Perez, MD (1) · Mary Horowitz, MD, MS (1) · Michael Haller, MD (1) · Michael Scordo, MD (1) · Richard E. Champlin, MD (1) · Vandana Raman, MD, MBBS (1)
PMID 21874061, PMID 24488560, PMID 35332298, PMID 35907408
2023 (1), R01CA132197 (1), U10HL069294 (1), U24CA076518 (1)